Cipla has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its manufacturing facility in Verna, Goa, India. The inspection, which took place from 6th to 17th April 2026, was a routine current Good Manufacturing Practices (cGMP) inspection as well as a Pre-Approval Inspection (PAI).
Upon conclusion of the inspection, Cipla received two inspectional observations in Form 483. The company has committed to working closely with the USFDA to address these observations comprehensively within the stipulated time frame.
The company has not disclosed the specific nature of the observations but has assured that it will take necessary measures to resolve the issues identified by the USFDA.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).